Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
NCT ID: NCT00362206
Last Updated: 2009-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
423 participants
INTERVENTIONAL
2006-09-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin
NCT00362934
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT00349375
Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
NCT00352183
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
NCT01674712
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
NCT00349284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 20mg
2
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 40 mg
3
Pravastatin
Pravastatin 40 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 20mg
Fenofibrate/Simvastatin
Combination of Fenofibrate and Simvastatin 40 mg
Pravastatin
Pravastatin 40 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or lactating women
* Contra-indication to fenofibrate or simvastatin or pravastatin
* Unstable or severe cardiac disease
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 40
Athens, , Greece
Site 39
Ioannina, , Greece
Site 41
Thessaloniki, , Greece
Site 37
Beer Yaakov, , Israel
Site 19
Haifa, , Israel
Site 22
Holon, , Israel
Site 18
Jerusalem, , Israel
Site 38
Kfar Saba, , Israel
Site 17
Ramat Gan, , Israel
Site 21
Ramat Gan, , Israel
Site 20
Rehovot, , Israel
Site 24
Safed, , Israel
Site 23
Tel Aviv, , Israel
Site 5
Arad, , Romania
Site 7
Bacau, , Romania
Site 1
Bucharest, , Romania
Site 6
Cluj-Napoca, , Romania
Site 4
Oradea, , Romania
Site 3
Ploieşti, , Romania
Site 2
Târgu Mureş, , Romania
Site 27
Barnaul, , Russia
Site 31
Kemerovo, , Russia
Site 32
Krasnoyarsk, , Russia
Site 25
Moscow, , Russia
Site 28
Novosibirsk, , Russia
Site 29
Saint Petersburg, , Russia
Site 26
Smolensk, , Russia
Site 30
Voronezh, , Russia
Site 10
Alberton, , South Africa
Site 9
Bloemfontein, , South Africa
Site 14
Cape Town, , South Africa
Site 35
Durban, , South Africa
Site 36
eMkhomazi, , South Africa
Site 33
Hillcrest, , South Africa
Site 34
Kempton Park, , South Africa
Site 16
Komatipoort, , South Africa
Site 13
Krugersdorp, , South Africa
Site 11
Parow, , South Africa
Site 12
Port Elizabeth, , South Africa
Site 8
Pretoria, , South Africa
Site 15
Worcester, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-000515-15
Identifier Type: -
Identifier Source: secondary_id
C LF0242780-01 05 04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.